Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Purchases $308,430.00 in Stock

Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Anthony S. Marucci acquired 11,500 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the acquisition, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Celldex Therapeutics Stock Down 4.1 %

NASDAQ:CLDX opened at $25.74 on Friday. The firm’s 50 day moving average is $32.65 and its two-hundred day moving average is $35.60. Celldex Therapeutics, Inc. has a fifty-two week low of $24.43 and a fifty-two week high of $53.18.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CLDX. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Citigroup started coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.25.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. KBC Group NV raised its holdings in Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $76,000. Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 1st quarter valued at $147,000. CANADA LIFE ASSURANCE Co boosted its position in Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. raised its position in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 1,582 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.